Profound Medical Corp (PROF) Stock Price, Quote & News

Company Profile

Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue....

Industry: Medical Devices

Sector: Healthcare

Phone: 647 476 1350

Fax: 647 847 3739

Website: www.profoundmedical.com

Address:

2400 Skymark Avenue, Unit 6, Mississauga, Canada

OfficialStocktwitsUser May. 13 at 4:59 AM

$PROF RSI: 54.48, MACD: 0.1930 Vol: 0.25, MA20: 6.87, MA50: 6.36 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

MarketBeat May. 8 at 9:09 PM

Profound Medical Q1 Earnings Call Highlights $PROF https://www.marketbeat.com/instant-alerts/profound-medical-q1-earnings-call-highlights-2

0 · Reply

alexpitti May. 8 at 1:47 PM

$PROF how do you lower guidance completely and have your stock spike

1 · Reply

alexpitti May. 7 at 8:46 PM

$PROF ugly guidance

1 · Reply

StocktwitsEarnings May. 7 at 8:28 PM

$PROF Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $0.19 down -47.22% YoY • Reported revenue of $5.34M up 103.62% YoY • Profound Medical Corp. projects total revenue for full-year 2026 to be approximately $25M, representing 56% growth, and expects full year 2026 gross margin to be 70% or higher.

1 · Reply

alexpitti May. 1 at 4:50 AM

$PROF profound is listed as experimental in nccn guidelines and needs 3 years of cancer data to change that

1 · Reply

SuperGreenToday Apr. 23 at 12:34 PM

$PROF Share Price: $6.95 Contract Selected: Oct 16, 2026 $10 Calls Buy Zone: $0.46 – $0.57 Target Zone: $0.76 – $0.93 Potential Upside: 56% ROI Time to Expiration: 175 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

alexpitti Apr. 20 at 8:18 PM

$PROF why is this stock rallying so much

1 · Reply

PantySniffer69420 Apr. 20 at 6:46 PM

$PROF I’m out. Gap filled at 7.11

0 · Reply

BioTuesdays Apr. 14 at 7:53 PM

$PROF The Society of Interventional Radiology (SIR) has highlighted the results of Profound Medical’s (NASDAQ: PROF; TSX: PRN) randomized post-market CAPTAIN trial demonstrating that men with localized, intermediate-risk prostate cancer recovered faster and experienced less short-term impact on their daily lives when treated with MRI-guided, transurethral ultrasound ablation (TULSA) compared with robotic prostatectomy (RP). https://biotuesdays.com/2026/04/14/sir-highlights-profounds-captain-study-results-showing-faster-recovery-with-tulsa-v-robotic-prostate-surgery/

0 · Reply

Profound Medical files to sell 921,428 common shares for holders

2026-05-08T12:46:30.000Z - 5 days ago

Profound Medical price target lowered to $10 from $12 at Stifel

2026-05-08T06:20:00.000Z - 5 days ago

Q1 2026 Profound Medical Corp Earnings Call Transcript

May 7, 2026, 4:30 PM EDT - 6 days ago

Profound Medical Earnings Call Transcript: Q1 2026

Thu, 07 May 2026 16:05:00 -0400 - 6 days ago

Profound Medical Reports Strong First Quarter 2026 Financial Results

2026-05-06T13:33:03.000Z - 7 days ago

Profound Medical Corp (PROF) Q1 2026 Earnings Report Preview: What to Expect

Apr 22, 2026, 10:00 AM EDT - 21 days ago

Profound Medical Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference

Tue, 21 Apr 2026 16:51:00 -0400 - 22 days ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF

Tue, 14 Apr 2026 07:30:00 -0400 - 4 weeks ago

Profound Medical to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference

Thu, 09 Apr 2026 09:00:00 -0400 - 4 weeks ago

Profound Medical Corp. Investigated by the Portnoy Law Firm

Wed, 01 Apr 2026 08:15:00 -0400 - 6 weeks ago

Incision-Free, MRI-Guided Prostate Treatment with Profound's TULSA-PRO® to be Featured in Multiple Presentations at the Upcoming 2026 Society of Interventional Radiology Scientific Meeting

Fri, 27 Mar 2026 07:45:00 -0400 - 6 weeks ago

Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure™ Milestone

Fri, 20 Mar 2026 06:23:16 -0400 - 7 weeks ago

Top 3 Health Care Stocks That Are Set To Fly In March

2026-03-13T16:26:46.000Z - 2 months ago

Profound Medical's (PROF) TULSA Procedure Shows Superior Safety Outcomes

Mar 13, 2026, 11:30 AM EDT - 2 months ago

Profound Medical Transcript: Status update

2026-03-13T14:40:28.000Z - 2 months ago

Profound Medical reports CAPTAIN trial meets primary safety endpoint

Fri, 13 Mar 2026 10:30:00 -0400 - 2 months ago

CAPTAIN Trial Comparing Profound's MRI-Guided TULSA Procedure™ to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence

2026-03-09T14:26:33.000Z - 2 months ago

Profound Medical (PROF) Awaits Key Clinical Data Presentation

2026-03-09T12:51:42.000Z - 2 months ago

Profound Medical pullback after Q4 report ‘misguided,’ says Lake Street

2026-03-06T05:02:23.000Z - 2 months ago

Profound Medical Corp (PROF) Q4 2025 Earnings Call Highlights: Revenue Surge and Strategic ...

2026-03-06T03:00:30.000Z - 2 months ago

Q4 2025 Profound Medical Corp Earnings Call Transcript

2026-03-05T21:59:47.000Z - 2 months ago

Profound Medical (PROF) Reports Q4 Revenue Below Expectations

2026-03-05T21:30:08.000Z - 2 months ago

Profound Medical Q4 Earnings Assessment

Mar 5, 2026, 4:30 PM EST - 2 months ago

Profound Medical Earnings Call Transcript: Q4 2025

2026-03-05T21:27:53.000Z - 2 months ago

Profound Medical reports Q4 EPS (27c), consensus (28c)

2026-03-04T20:03:05.000Z - 2 months ago

Profound Medical's Earnings: A Preview

2026-03-04T12:22:47.000Z - 2 months ago

Profound Medical Corp (PROF) Q4 2025 Earnings Report Preview: What To Expect

2026-02-05T13:37:34.000Z - 3 months ago

Profound Medical (PROF) Celebrates Milestone in Poland with 500th Sonalleve Procedure

2026-02-05T13:12:03.000Z - 3 months ago

Profound Medical, Pro Familia completed 500th Sonalleve Procedure

2026-01-15T12:54:59.000Z - 4 months ago

Profound Medical (PROF) Introduces TULSA-PRO at Mount Sinai Hospital

2026-01-15T12:36:14.000Z - 4 months ago

Profound Medical announces Mount Sinai Hospital treated patient with TULSA-PRO

2026-01-12T13:56:40.000Z - 4 months ago

Profound Medical (PROF) Surpasses Installation Goal with TULSA-PRO System

2026-01-12T13:36:38.000Z - 4 months ago

Profound Medical surpasses 2025 TULSA-PRO installed base goal

2026-01-07T19:32:18.000Z - 4 months ago

Profound Medical (PROF) Sees Price Target Boost by Lake Street | PROF Stock News

2026-01-07T13:46:03.000Z - 4 months ago

Profound Medical price target raised to $12 from $11 at Lake Street

2026-01-06T13:27:39.000Z - 4 months ago

Profound Medical (PROF) Marks Milestone at Johns Hopkins Hospital

2026-01-06T12:50:20.000Z - 4 months ago

Profound Medical says Johns Hopkins treats first commercial TULSA-PRO case

Tue, 06 Jan 2026 07:45:00 -0500 - 4 months ago

Johns Hopkins Medicine Treats First Commercial TULSA-PRO® Case

Tue, 30 Dec 2025 16:30:00 -0500 - 4 months ago

Profound Medical Corp. Announces Closing of Private Placement

Wed, 24 Dec 2025 13:15:00 -0500 - 5 months ago

Profound Medical Corp. Announces Upsize of Private Placement

Tue, 23 Dec 2025 08:00:00 -0500 - 5 months ago

Profound Medical Corp. Closes $36 Million Registered Direct Offering; Expects to Complete Subsequent Private Placement On or Before December 30th

2025-12-19T13:50:40.000Z - 5 months ago

Profound Medical prices 5.14M shares at $7.00 in registered direct offering

Fri, 19 Dec 2025 08:45:00 -0500 - 5 months ago

Profound Medical Corp. Announces Pricing of up to $40 Million Financing Comprised of a $36 Million Registered Direct Offering and a Subsequent $4 Million Private Placement

2025-12-05T14:55:03.000Z - 5 months ago

Wall Street Analysts Think Profound Medical (PROF) Could Surge 82.37%: Read This Before Placing a Bet

Thu, 04 Dec 2025 17:00:00 -0500 - 5 months ago

Stanford Medicine's Dr. Pejman Ghanouni Receives RSNA's Cum Laude Award for CAPTAIN Perioperative Data Presentation

2025-11-28T13:26:09.000Z - 5 months ago

Profound Medical (PROF) Readies Launch of TULSA-AI Module for BPH Treatment

2025-11-28T12:50:06.000Z - 5 months ago

Profound Medical to launch AI-powered BPH module

Fri, 28 Nov 2025 07:45:00 -0500 - 5 months ago

Profound Medical to Launch AI-Powered BPH Module, Present New TULSA-PRO® Clinical Data, at RSNA and SUO Meetings

2025-11-24T14:55:04.000Z - 6 months ago

Profound Medical (PROF) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

2025-11-24T14:55:03.000Z - 6 months ago

Profound Medical (PROF) Just Flashed Golden Cross Signal: Do You Buy?

Nov 18, 2025, 4:15 PM EST - 6 months ago

Profound Medical Celebrates The Hong Center's 200th Independent TULSA Procedure for Prostate Disease

2025-11-16T10:55:05.000Z - 6 months ago

Profound Medical reports Q3 EPS (26c), consensus (38c)

2025-11-16T10:31:21.000Z - 6 months ago

Profound Medical reports Q3 EPS (26c), consensus (38c)

2025-11-13T22:10:18.000Z - 6 months ago

Profound Medical files $150M mixed securities shelf

2025-11-13T21:46:00.000Z - 6 months ago

Profound Medical reports Q3 EPS (26c), consensus (38c)

Nov 13, 2025, 4:05 PM EST - 6 months ago

Profound Medical Reports Strong Third Quarter 2025 Financial Results

2025-11-12T15:45:31.000Z - 6 months ago

Profound Medical management to meet virtually with Lake Street

2025-11-12T13:40:36.000Z - 6 months ago

Profound Medical announces distribution agreement with Getz Healthcare

Nov 12, 2025, 8:30 AM EST - 6 months ago

Profound Medical Announces Strategic Distribution Agreement with Getz Healthcare to Bring TULSA-PRO® to Australia and New Zealand

Nov 11, 2025, 4:15 PM EST - 6 months ago

Profound Medical Inks Exclusive Distribution Agreement for TULSA-PRO® and Sonalleve® with Al Faisaliah Medical Systems in Saudi Arabia

2025-11-10T22:10:17.000Z - 6 months ago

Profound Medical regains exclusive distribution rights for Tulsa-Pro in Canada

2025-10-16T12:16:53.000Z - 7 months ago

Profound Medical announces Busch Center completed 500th TULSA procedure

Oct 14, 2025, 8:30 AM EDT - 7 months ago

Profound Medical to Participate in the Stifel 2025 Healthcare Conference

Oct 7, 2025, 7:45 AM EDT - 7 months ago

Profound Medical Achieves Record Preliminary Unaudited Revenue for the 2025 Third Quarter

Sep 23, 2025, 8:00 AM EDT - 8 months ago

Texas Prostate and Dallas Medical Center Launch First-of-its-Kind TULSA Program, Expanding Access to Advanced Prostate Treatment

Aug 28, 2025, 8:00 AM EDT - 9 months ago

Profound Medical to Participate in Lake Street's 9th Annual Best Ideas Growth Conference

Aug 14, 2025, 4:05 PM EDT - 9 months ago

Profound Medical Announces Second Quarter 2025 Financial Results

Jul 24, 2025, 5:00 PM EDT - 10 months ago

Profound Medical to Release Second Quarter 2025 Financial Results on August 14 – Conference Call to Follow

May 14, 2025, 4:45 PM EDT - 1 year ago

Profound Medical Annual General and Special Meeting of Shareholders Voting Results

Apr 30, 2025, 4:30 PM EDT - 1 year ago

Profound Medical to Participate in the 2025 Bloom Burton & Co. Healthcare Investor Conference

Apr 29, 2025, 7:30 AM EDT - 1 year ago

Initial Perioperative Data from CAPTAIN Randomized Trial Demonstrate MRI-Guided TULSA Provides Statistically Significant Improvement of Post-Operative Experience Vs. Robotic Radical Prostatectomy

Apr 15, 2025, 7:45 AM EDT - 1 year ago

Profound Medical AUA 2025 Investor Event Agenda

Feb 13, 2025, 5:00 PM EST - 1 year ago

Profound Medical to Release Fourth Quarter and Full Year 2024 Financial Results on March 6 – Conference Call to Follow

Jan 8, 2025, 7:30 AM EST - 1 year ago

Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Revenues

Jan 6, 2025, 8:15 AM EST - 1 year ago

Profound Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 10, 2024, 9:55 AM EST - 1 year ago

Profound Medical Announces Closing of US$40.25 Million Underwritten Public Offering of Common Shares

OfficialStocktwitsUser May. 13 at 4:59 AM

0 · Reply

MarketBeat May. 8 at 9:09 PM

Profound Medical Q1 Earnings Call Highlights $PROF https://www.marketbeat.com/instant-alerts/profound-medical-q1-earnings-call-highlights-2

0 · Reply

alexpitti May. 8 at 1:47 PM

$PROF how do you lower guidance completely and have your stock spike

1 · Reply

alexpitti May. 7 at 8:46 PM

$PROF ugly guidance

1 · Reply

StocktwitsEarnings May. 7 at 8:28 PM

1 · Reply

alexpitti May. 1 at 4:50 AM

$PROF profound is listed as experimental in nccn guidelines and needs 3 years of cancer data to change that

1 · Reply

SuperGreenToday Apr. 23 at 12:34 PM

0 · Reply

alexpitti Apr. 20 at 8:18 PM

$PROF why is this stock rallying so much

1 · Reply

PantySniffer69420 Apr. 20 at 6:46 PM

$PROF I’m out. Gap filled at 7.11

0 · Reply

BioTuesdays Apr. 14 at 7:53 PM

0 · Reply

prismmarketview Apr. 7 at 3:15 PM

PRISM Men’s Health Spotlight We’re adding @ProfoundMedical (Nasdaq: $PROF) to the PRISM MedTech Index. Profound is advancing an incision-free approach to prostate disease with its TULSA-PRO system, combining MRI guidance and AI-powered ultrasound ablation to precisely target tissue while preserving key functions such as continence and erectile function. Recent updates point to strong commercial momentum, record revenue growth, and encouraging clinical data from the CAPTAIN trial. A differentiated platform in a large and evolving category within men’s health. Welcome to the index, $PROF. #ProfoundMedical #UltrasoundAblation https://prismmarketview.com/companies/profound-medical-corp/

0 · Reply

PantySniffer69420 Mar. 31 at 5:56 PM

$PROF

0 · Reply

alexpitti Mar. 30 at 9:25 PM

guys follow me. i'm back on twitter $DCTH $STXS $RCEL $ABEO $PROF https://x.com/alex__pitti

0 · Reply

johntarlick Mar. 28 at 10:41 AM

$PROF well that's now the 2nd time a news item related to texas prostate has bumped the price substantially, even though texas prostate isn't doing anything different than any other tulsa treatment provider of the past 6 years has done, and continues to do. wish i knew what the markets evidently know.

1 · Reply

PantySniffer69420 Mar. 27 at 1:34 PM

$PROF

0 · Reply

BioTuesdays Mar. 27 at 12:54 PM

$PROF has announced that Texas Prostate, led by Dr. James Cochran, has achieved its 100th TULSA Procedure performed in Dallas Medical Center’s state-of-the-art MRI suite. https://biotuesdays.com/2026/03/27/profound-congratulates-texas-prostates-100th-tulsa-procedure-milestone/

0 · Reply

PantySniffer69420 Mar. 26 at 2:38 PM

$PROF

0 · Reply

BioTuesdays Mar. 16 at 5:23 PM

$PROF has announced superiority on the prespecified, primary safety endpoint in the Level 1 post-market CAPTAIN randomized controlled trial comparing the TULSA Procedure with robotic radical prostatectomy (RP) in men with organ-confined, intermediate-risk, Gleason Score 7 (Grade Group 2 and 3) prostate cancer. https://biotuesdays.com/2026/03/16/trial-finds-profounds-tulsa-procedure-significantly-improves-erectile-function-and-continence-vs-robotic-radical-prostatectomy/

1 · Reply

PantySniffer69420 Mar. 13 at 12:23 AM

$PROF

0 · Reply

PantySniffer69420 Mar. 10 at 3:04 PM

$PROF Here for the gap fill then out.

0 · Reply

QES Mar. 9 at 9:22 PM

$PROF New account coming in Arizona. https://www.linkedin.com/feed/update/urn:li:activity:7435674668663001088/

0 · Reply

StreetwiseReports Mar. 9 at 6:31 PM

Medical Co.'s TULSA-PRO Installed Base Growth and CAPTAIN Trial Data Could Accelerate Adoption in 2026 https://ow.ly/iPIE50YrtLI Leede Financial maintained its rating on Profound Medical Corp. ($PROF:NASDAQ; PRN:TSX), citing strong TULSA-PRO capital sales, expanding installed base, and upcoming CAPTAIN trial results at EAU meeting as key catalysts.

0 · Reply

Market Cap	263.45M
Revenue (ttm)	16.10M
Net Income (ttm)	-42.57M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-264.41%
Debt to Equity Ratio	0.08

Volume	55,400
Avg Vol	214,806
Day's Range	N/A - N/A
Shares Out	36.34M
Stochastic %K	46%
Beta	0.73
Analysts	Strong Sell
Price Target	$11.12